Policy & Regulation
Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma
7 May 2026 - Biotechnology company Partner Therapeutics Inc (PTx) announced on Wednesday that the US Food and Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNP...
Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma
7 May 2026 - Clinical-stage biotechnology company Diakonos Oncology Corp announced on Wednesday that the US Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021 (dubodencel...
Racura Oncology identifies mechanism of action for (E,E)-bisantrene
...
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
6 May 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Wednesday that it has agreed to fully acquire Perfuse Therapeutics Inc, strengthening its phar...
NextCell Pharma and FUJIFILM Biosciences launch global MSC research product
...
ZYUS Life Sciences receives second US pain management patent
6 May 2026 - Canada-based ZYUS Life Sciences Corporation (TSXV:ZYUS), a clinical-stage life sciences company focused on the development and commercialisation of novel non-opioid drug candidates for pa...